Specific role of phosphodiesterase 4B in lipopolysaccharide-induced signaling in mouse macrophages

被引:193
作者
Jin, SLC [1 ]
Lan, L [1 ]
Zoudilova, M [1 ]
Conti, M [1 ]
机构
[1] Stanford Univ, Sch Med, Dept Obstet & Gynecol, Div Reprod Biol, Stanford, CA 94305 USA
关键词
D O I
10.4049/jimmunol.175.3.1523
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Cyclic nucleotide signaling functions as a negative modulator of inflammatory cell responses, and type 4 phosphodiesterases (PDE4) are important regulators of this pathway. In this study, we provide evidence that only one of the three PDE4 genes expressed in mouse peritoneal macrophages is involved in the control of TLR signaling. In these cells, LPS stimulation of TLR caused a major up-regulation of PDE4B but not the paralogs PDE4A or PDE4D. Only ablation of PDE413 impacted LPS signaling and TNF-alpha production. TNF-alpha mRNA and protein were decreased by > 50% in PDE4B(-/-), but not in PDE4A(-/-) or PDE4D(-/-) macrophages. The PDE4 selective inhibitors rolipram and roflumilast had no additional inhibitory effect in macrophages deficient in PDE4B, but suppressed the TNF-a response in the other PDE4 null cells. The inhibition of TNF-a production that follows either genetic ablation or acute inhibition of PDE4B is cAMP-dependent and requires protein kinase A activity. However, no global changes in cAMP concentration were observed in the PDE4B(-/-) macrophages. Moreover, ablation of PDE4B protected mice from LPS-induced shock, suggesting that altered TLR signaling is retained in vivo. These findings demonstrate the highly specialized function of PDE4B in macrophages and its critical role in LPS signaling. Moreover, they provide proof of concept that a PDE4 inhibitor with subtype selectivity retains useful pharmacological effects.
引用
收藏
页码:1523 / 1531
页数:9
相关论文
共 45 条
[1]  
ALVAREZ R, 1995, MOL PHARMACOL, V48, P616
[2]   Regulation of T-cell activation by phosphodiesterase 4B2 requires its dynamic redistribution during immunological synapse formation [J].
Arp, J ;
Kirchhof, MG ;
Baroja, ML ;
Nazarian, SH ;
Chau, TA ;
Strathdee, CA ;
Ball, EH ;
Madrenas, J .
MOLECULAR AND CELLULAR BIOLOGY, 2003, 23 (22) :8042-8057
[3]   PDE4 inhibition: a novel approach for the treatment of inflammatory bowel disease [J].
Banner, KH ;
Trevethick, MA .
TRENDS IN PHARMACOLOGICAL SCIENCES, 2004, 25 (08) :430-436
[4]   Differential expression of PDE4 cAMP phosphodiesterase isoforms in inflammatory cells of smokers with COPD, smokers without COPD, and nonsmokers [J].
Barber, R ;
Baillie, GS ;
Bergmann, R ;
Shepherd, MC ;
Sepper, R ;
Houslay, MD ;
Van Heeke, G .
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, 2004, 287 (02) :L332-L343
[5]  
Barnette M S, 2000, Curr Opin Pulm Med, V6, P164, DOI 10.1097/00063198-200003000-00014
[6]  
Barnette MS, 1998, J PHARMACOL EXP THER, V284, P420
[7]   Differentiation of human monocytes in vitro with granulocyte-macrophage colony-stimulating factor and macrophage colony-stimulating factor produces distinct changes in cGMP phosphodiesterase expression [J].
Bender, AT ;
Ostenson, CL ;
Giordano, D ;
Beavo, JA .
CELLULAR SIGNALLING, 2004, 16 (03) :365-374
[8]  
BEUTLER B, 1993, CRIT CARE MED, V21, pS423
[9]   The two NF-κB activation pathways and their role in innate and adaptive immunity [J].
Bonizzi, G ;
Karin, M .
TRENDS IN IMMUNOLOGY, 2004, 25 (06) :280-288
[10]  
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3